Company news

Dyadic International, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dyadic Expands Global Presence with Participation in Key Industry Events

October 8, 2024

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

September 22, 2024

Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

August 12, 2024

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

June 27, 2024

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 13, 2024

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

April 29, 2024

Dyadic Reports 2023 Full Year Results and Recent Company Progress

March 27, 2024

Dyadic Announces Change in Board and Management Leadership Roles

March 27, 2024

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

March 25, 2024

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

March 10, 2024

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

February 27, 2024

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

February 20, 2024

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

February 12, 2024

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

February 5, 2024

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

November 28, 2023

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 7, 2023

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

October 24, 2023

Dyadic Appoints Doug Pace to Its Executive Leadership Team

October 8, 2023

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic V...

October 4, 2023

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

September 25, 2023

Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™

September 18, 2023

Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 8, 2023

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

August 6, 2023

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

July 25, 2023

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

July 23, 2023

Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity

June 20, 2023

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 9, 2023

Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™

May 7, 2023

Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

April 25, 2023

Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

April 17, 2023

Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent

April 11, 2023

Dyadic Reports 2022 Year End Results and Recent Company Progress

March 28, 2023

Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

March 14, 2023

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

March 6, 2023

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

January 23, 2023

Dyadic Announces Sale of Equity Interest in Alphazyme

January 18, 2023

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

November 9, 2022

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

October 26, 2022

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

October 26, 2022

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

October 3, 2022

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

August 9, 2022

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

July 26, 2022

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

May 10, 2022

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

May 8, 2022

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

April 27, 2022

Dyadic Reports 2021 Year End Results and Recent Company Progress

March 28, 2022

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

February 9, 2022

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

January 19, 2022

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

December 21, 2021

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

December 16, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.